166 CELLULAR AND MOLECULAR CHARACTERISTICS OF CHONDROCYTES DERIVED FROM PATIENTS WITH OSTEOARTHRITIS REVEAL THEIR APPLICABILITY IN MATRIX-ASSISTED AUTOLOGOUS CHONDROCYTE TRANSPLANTATION  by Ringe, J. et al.
Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256 S81
compared to the other subpopulations. CD105 and Runx2 were shown by
immunohistochemistry and genetic analysis to have signiﬁcantly higher
expression CD271+ subpopulation than the other subpopulations.
Conclusions: Spheroids formed from CD271-enriched and CD73-enriched
MSCs from normal human synovial membranes mimic the native cartilage
extracellular matrix more closely than CD106+ MSCs and are possible
candidates for use in cartilage tissue engineering. Both cell types have
potential for promoting the differentiation of MSCs into chondrocytes,
presenting new possibilities for achieving intrinsic cartilage repair.
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DIRECT RAAV-MEDIATED IGF-I OVEREXPRESSION ENHANCES ARTICULAR
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Purpose: Therapeutic gene transfer might be a means to enhance the
reparative activities in articular cartilage lesions. We previously reported
that recombinant adeno-associated viral (rAAV) vectors are capable of de-
livering transgene sequences to articular cartilage defects in experimental
models over extended periods of time. In the present study, we tested the
hypothesis that eﬃcient and sustained overexpression of IGF-I via direct
application of rAAV enhances the healing of osteochondral defects created
in the knee joints of rabbits in vivo.
Methods: rAAV were packaged, puriﬁed by dialysis, and titrated by real-
time PCR. rAAV-lacZ carries the E. coli beta-galactosidase (β-gal) marker
gene (lacZ) controlled by the CMV-IE promoter/enhancer. A human insulin-
like growth factor-I (hIGF-I) cDNA was cloned in rAAV-lacZ instead of lacZ
to produce rAAV-hIGF-I. Two osteochondral defects (3.2-mm in diameter)
were created in each patellar groove of Chinchilla bastard rabbits (n = 8).
Each animal received alternatively 10 μ l rAAV-hIGF-I per defect on one
knee (IGF-I-treated defects) and 10 μl rAAV-lacZ per defect on the con-
tralateral knee (control defects). At 3 weeks post operation, cartilage repair
was assessed based on safranin O/hematoxylin eosin-stained sections using
a histological grading system. A total of 145 paraﬃn-embedded sections
(5 μm) were scored independently by two individuals that were blinded
with respect to the treatment. Points for each category and total score
were compared between the groups using a mixed general linear model
with repeated-measures analysis of variance. Indirect immunohistochemi-
cal staining was also performed to detect β-gal, hIGF-I, and type-II collagen.
The DNA, proteoglycan, and type-II collagen contents of the repair tissue
within the defects were measured using Hoechst 33258, by binding to
DMMB dye, and by ELISA, respectively. Data are expressed as mean ± SD.
The t-test and the Mann-Whitney Rank Sum Test were employed where
appropriate.
Figure 1. Safranin O staining (A, B) and type-II collagen immunoreactivity (C, D) in osteo-
chondral defects 3 weeks after vector application (A, C: rAAV-lacZ; B, D: rAAV-hIGF-I).
Magniﬁcation ×2.
Results: Following direct application of the vectors in vivo, there were no
signs of synovitis, adhesions, or adverse reactions, and no macroscopically
descriptive differences between the IGF-I-treated and control knees. β-gal
activity was restricted to the control defects, whereas IGF-I expression
was present only in the IGF-I-treated defects. After 3 weeks, enhanced
tissue healing was observed in the IGF-I-treated defects (Fig. 1). Improved
individual parameter scores were observed for defect ﬁlling, integration,
matrix staining, cellular morphology, defect and surface architecture, new
subchondral bone formation (all P<0.001) and tidemark (P<0.01) of the
IGF-I-treated defects, with also a signiﬁcantly improved total score vis a
vis control treatment (P<0.001). Immunoreactivity to type-II collagen was
more intense and regular in the IGF-I-treated defects (Fig. 1). Biochemical
analyses performed on the repair tissue from the defects revealed that
treatment with rAAV-hIGF-I promoted a signiﬁcant increase in the DNA
(3.2-fold; P<0.001), proteoglycan (1.2-fold; P = 0.01), and type-II collagen
contents (2.8-fold; P<0.001).
Conclusions: The data indicate that IGF-I can be overexpressed in osteo-
chondral defects in vivo via rAAV transduction, leading to the production
of a recombinant IGF-I factor that is capable of signiﬁcantly improving the
healing of the defects, stimulating both cell proliferation and extracellular
matrix synthesis. The results suggest that therapeutic rAAV may have value
in enhancing cartilage repair by application to sites of cartilage damage.
Further studies are required to evaluate the long-term properties of the
repair tissue.
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Purpose: Cartilage defects arise primarily due to traumatic or degenerative
changes and in the medium to long-term often result in osteoarthritis and
total joint replacement. One aim of modern orthopaedics is to avoid TJR.
For traumatic and small focal degenerative cartilage defects, in the recent
years promising treatment options like lavage, abrasion, osteochondral au-
tograft transfer, microfracture, cell-free implants, autologous chondrocyte
transplantation and matrix assisted ACT have been developed. However,
these therapies cannot completely arrest OA progression and currently are
not applied for the treatment of large OA defects. This is partly due to
a lack of knowledge regarding the cellular and molecular characteristics
of OA chondrocytes. The extracellular matrix is the functional element in
cartilage and its degradation is central in the pathogenetic process in OA.
In addition, new formation of ECM is crucial in OA chondrocyte based
therapies. Therefore, the aim of our study was to provide a more complete
picture of the cellular and molecular alterations in OA cartilage and to
analyze cartilage formation by OA-chondrocytes.
Methods: Human articular cartilage biopsies were collected from OA
patients as well as healthy normal donors. RNA was isolated from the
biopsies and subjected to genome-wide microarray analysis. Important
results were veriﬁed using qPCR and immunohistochemistry. Furthermore,
chondrocytes were harvested from such biopsies applying protocols used
for ACT. Their chondrogenic potential was studied in high-density pel-
let and hyaff-11 cultures by proteoglycan and collagen type II staining.
Moreover, chondrocytes cultured in monolayer and hyaff-11 scaffolds were
subjected to microarray gene expression proﬁling. Again, expression data
were veriﬁed by qPCR.
Results: We detected genes already associated with normal cartilage and
alterations in OA cartilage but also detected new candidates not previously
associated with this disease. Here, the expression of genes coding for colla-
gens (COL8A2, COL13-15A1) or related to bone formation (CLEC3B, CDH11,
GPNMB, CLEC3A, CHST11, MSX1-2) was signiﬁcantly higher in native OA
cartilage than in native ND cartilage. In 3D hyaff-11 cultures, chondrocytes
from ND and OA donors secreted comparable amounts of ECM components
like proteoglycans and collagen type II. Expression of cartilage marker
genes (ACAN, COL2A1, COMP, SOX9) and genes involved in matrix syn-
thesis (BGN, COL9A2, COL11A1) was highly induced in 3D ND and OA
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chondrocyte cultures. Genes already associated with hypertrophic cartilage
or OA (ALPL, COL3A1, COL10A1, MMP13, POSTN, PTH1R, RUNX2) were not
signiﬁcantly regulated between the two donor groups. The expression of
661 genes was differentially regulated between OA and ND chondrocytes
cultured in monolayer. During scaffold culture, the differences diminished,
and only 184 genes were differentially regulated.
Conclusions: All in all, our data conﬁrm already known data on many
characteristic features of native OA cartilage, but we have also identiﬁed
new candidate genes that are differentially expressed during OA. For the
development of new OA cartilage treatment strategies, such a deeper
insight into phenotypical alterations occurring in OA is important. Only a
few genes were differentially expressed between OA and ND chondrocytes
in hyaff-11 culture. So, the risk of generating hypertrophic cartilage does
not seem to be increased for OA chondrocytes. Importantly, our ﬁndings
suggest that the chondrogenic capacity is not signiﬁcantly affected by OA,
and OA chondrocytes fulﬁll the requirements for ACT.
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Purpose: Osteoarthritis (OA) is a degenerative disease characterized by an
erosion of articular cartilage. In this pathology, the expression of type II col-
lagen and aggrecans, the speciﬁc markers of cartilage, is strongly decreased
while that of type I collagen is increased, a process called dedifferentiation.
Several methods have been developped to try to restore the chondrocyte
phenotype, like autologous osteochondral mosaic implantation, but they
did not allow to obtain satisfying results. Another promising therapy is
based on the Brittberg’s procedure which consists to autologous chondro-
cyte implantation (ACI). However, chondrocyte ampliﬁcation in vitro before
the transplantation in this method leads to a cell dedifferentiation, and
once the chondrocytes are implanted in vivo, a ﬁbro-cartilage is formed
instead of a hyaline cartilage.
Methods: To prevent this phenotype loss, we have developped another
alternative approach in which HAC (Human Articular Chondrocytes) are
cultured in type I collagen sponges, under low oxygen tension (5%),
and incubated with or without BMP-2 (50 ng/ml). The morphology of
chondrocytes cultured in collagen sponges was analyzed using scanning
and transmission electron microscopy and their phenotype was evaluated
using immunohistochemistry. Chondrocyte phenotype was also analyzed
by real time RT-PCR to follow the expression of speciﬁc (type II collagen,
aggrecans) and non-speciﬁc markers (types I and X collagens) of articular
cartilage. Protein expression was also quantiﬁed in Western-blot and ELISA
experiments. Furthermore, the effect of BMP2-treatment on transcriptional
activity of COL2A1 gene and the DNA binding activities of several transcrip-
tion factors using EMSA experiments was determined. Finally, particular
inhibitors were assayed to improve the chondrocyte phenotype recovery.
Results: Our data show that both mRNA and protein steady-state levels
of type II collagen and aggrecans are increased when chondrocytes are
incubated in the presence of BMP-2. Additionally, a redifferentiation of
dedifferentiated chondrocyte is observed in type I collagen sponges without
no sign of hypertrophy induction estimated by the expression level of type
X collagen. These data were further corroborated by immunohistochem-
istry analysis which gave the same results. Moreover, we show that BMP-2
increases COL2A1 gene transcription through the speciﬁc enhancer region
located in the ﬁrst intron. Gel retardation assays demonstrate that BMP-2
induces an increase in the DNA-binding activity of the transcription factors
Sox9 and Sp1 to the speciﬁc enhancer of COL2A1 and are responsible
for the observed transcriptional effects. Finally, by using some particular
inhibitors, some genes induced during the OA process were shown to be
down-regulated and this will be a necessary step for the full recovery of
the chondrocyte phenotype.
Conclusions: In summary, our results demonstrate that the HAC phenotype
can be stabilized by culturing these cells in a 3D scaffold, in hypoxic
conditions, and in the presence of BMP-2. Our short-term objective will be
to evaluate the behavior of such differentiated chondrocytes in vivo, after
sub-cutaneous implantation in the nude mouse model, in order to deter-
mine if a hyaline- or a ﬁbro-cartilage is formed. As a conclusion, this study
provides new insights into the molecular mechanism of stability and/or
induction of chondrocyte phenotype, an absolutely necessary step, that will
allow to develop new methods for autologous chondrocyte implantation in
humans.
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AN EARLY INFLAMMATORY RESPONSE DETERMINES THE ONSET OF
CHONDROGENESIS
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Purpose: Inﬂammatory response mediators such as iNOS, COX-2 and NF-κB
are essential for fracture healing and may contribute to the process of
endochondral ossiﬁcation. Although the function of these mediators has
mainly been studied during cartilage degeneration and the osteogenic
phase of endochondral bone formation, their role during chondrogenesis
is poorly understood. We hypothesized that the onset of chondrogenesis
from mesenchymal progenitors is regulated by inﬂammatory signaling.
Methods: The chondroprogenitor cell line ATDC5 was differentiated in the
presence of NF-κB activating agents LPS (0.1 ng/ml) or TNFα (10 ng/ml) or
with the NF-κB inhibitors TLCK (50, 100 μM) or parthenolide (1, 10 μM).
In addition a knockdown of p65 was targeted by RNAi. NF-κB activation
was determined by analyzing p65 nuclear translocation and expression of
NF-κB targets by RT-qPCR and immunoblot. Chondrocyte speciﬁc markers
were analyzed by RT-qPCR and immunoblot. Similar experiments were
performed using human bone marrow stem cells (hBMSCs). HBMSCs were
obtained from iliac crest bone marrow aspirate from 5 young, genetically
healthy, individuals. Chondrogenesis was performed in monolayer culture.
Results: ATDC5 cells were triggered for chondrogenesis and after 14 days
Col2A1 and Col10A1 mRNAs and proteins were abundantly expressed.
During the very early onset of differentiation key chondrogenic controller
Sox9 was upregulated (2-8 hours), which was accompanied by upregulation
of inﬂammatory mediators COX-2, iNOS, IL-6 and TNFα. This inﬂammatory
response was preceded by NF-κB activation at 30-60 minutes in differenti-
ation, indicating that expression of these inﬂammatory mediators, as well
as Sox9 expression may be regulated by NF-κB activation. To investigate
the role of NF-κB activation during early chondrogenesis, NF-κB signalling
was stimulated by very low concentrations of LPS or TNFα. Surprisingly,
this resulted in an increased upregulation of Sox9 at early time points
and increased Col2A1 and Col10A1 expression late in differentiation.
Importantly, inhibition or genetic knockdown of NF-κB resulted in inhibi-
tion of chondrogenic differentiation, as determined by Sox9, Col2A1 and
Col10A1 expression. Indicating that the induction of Sox9 and subsequent
chondrogenesis are dependent on this inﬂammatory response and NF-κB
activation.
To verify these results in a independent human system, hBMSCs were
used. In concert with our ﬁndings in ATDC5 cells, early chondrogenesis
of hBMSCs was also accompanied with a similar inﬂammatory response
and upregulation of Sox9 (2-8 hours). Nuclear translocation of NF-κB was
detected at 1-4 hours in differentiation. Stimulation of NF-κB activity with a
low LPS concentration resulted in increased Col2A1 protein levels, whereas
inhibition of NF-κB with TLCK resulted in decreased Col2A1 levels.
Conclusions: We here show for the ﬁrst time that a cell-intrinsic
inﬂammation-like signaling response at the onset of chondrogenesis
critically determines the cellular differentiation program by regulating
key chondrogenic pathways. Our ﬁndings demonstrate that inﬂamma-
tory responses are not solely associated with cartilage degeneration, but,
paradoxically, represent an obligatory element in early chondrogenesis.
Importantly, our results provide novel stratagies to improve the outcome
of cartilage regenerative techniques.
